
| Species: | Rabbit |
| Applications: | WB IHC IF |
| Immunogen Range: | KLH conjugated synthetic peptide derived from human BCL9 |
| Clonality: | Polyclonal Antibody |
| Isotype: | IgG |
| GENE ID: | 101060700 |
| Swiss Prot: | |
| Synonyms: | B-cell CLL/lymphoma 9, BCL 9, BCL-9, DLNB11, Legless homolog, B-cell CLL/lymphoma 9-like, LGS, BCL9_HUMAN. |
| Purification: | Purified by Protein A. |
| Storage: | Aqueous buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at -20℃ for 12 months |
| Background: | Bcl-9L is a 1,499 amino acid protein that localizes to the nucleus and contains a specialized C-terminal domain that is important for its overall activity. Expressed in breast tissue, as well as in eye, lung, prostate and various carcinomas, Bcl-9L functions as a transcriptional activator that forms a complex with Parafibromin and ?2-catenin and is thought promote the transcriptional activity of Parafibromin and enhance the neoplastic transforming activity of ?2-catenin. Bcl-9L exists as multiple alternatively spliced isoforms and is thought to be involved in tumorigenesis, possibly playing a role in tumor transformation and metastasis. The gene encoding Bcl-9L maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are associated with defects in genes that maps to chromosome 11. |
| Caculated MW: | / |
| Observed MW: | Refer to Figures |
| Applications: |
WB 1:100-1:1000 IHC 1:100-1:500 IF 1:50-1:200 |
| Reacitivity: | Human, Mouse, Rat |